These results indicate that the genetic depletion and pharmaceutical inhibition of TYRO3 lead to decreases in bladder cancer cell viability and tumour outgrowth ability, identifying TYRO3 as a potential therapeutic target. This evidence concerns the gene TYRO3 and neoplasm.